#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Lip and/or oral cavity cancer Hepatic angiosarcoma Paget's disease of the vulva Extraskeletal ossification Pericarditis Mastocytosis Cryoglobulinaemia Exudative retinopathy Acquired ATTR amyloidosis Infertility male Metastases to central nervous system Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Stress cardiomyopathy Hepatitis D Chronic myeloid leukaemia (in remission) More trials…

    Learn about Rare Diseases

    Methylmalonic acidaemia – Life with Disease Factor VIII deficiency – Trials in Disease Mitochondrial myopathy Pleural mesothelioma malignant – Trials in Disease Burkitt’s lymphoma – Life with Disease Biotinidase deficiency – Life with Disease Primary hyperoxaluria – Basic Information Synovial sarcoma metastatic – Basic Information Acquired haemophilia – Basic Information Adrenogenital syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Palonosetron Hydrochloride ULTEVURSEN Adenosine Doxecitine Fexofenadine Hydrochloride Lib-01 Monohydrate OBI-821 L-Threonine Viltolarsen Cefiderocol Lactose Sertraline Hydrochloride Edoxaban Goserelin Acetate Azd8630 Azelastine Mosliciguat Milnacipran Hydrochloride Vitamin A Bp Damoctocog Alfa Pegol More therapies…

    Learn about Your Condition

    Vertigo Actinic cheilitis Familial mediterranean fever Colorectal adenoma Abdominal wall pain Merycism Clostridium difficile colitis Psychological trauma Sjogren's syndrome Septic shock Tubulointerstitial nephritis Aplasia pure red cell Hot flush Dermatomyositis Tendon injury More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Synovial Hypertrophy in Patients with Hemophilia A Using Efanesoctocog Alfa Prophylaxis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Factor VIII deficiency
    Investigated Drugs:
    • Efanesoctocog Alfa
    Italy Norway Spain Sweden

  • Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Barzolvolimab
    • Epinephrine
    Bulgaria Croatia Germany Hungary Italy Lithuania +4

  • Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Ceralasertib
    • Docetaxel
    • Durvalumab
    Belgium France Germany Hungary Ireland Italy +4

  • Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    Investigated Drugs:
    • Domvanalimab
    • Durvalumab
    • Infliximab
    Belgium France Germany Greece Hungary Italy +4

  • Study of MK-7684A and Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Vibostolimab
    • Bevacizumab
    • Capecitabine
    France Germany Italy The Netherlands Poland Spain

  • Study Comparing MK-2870 with Chemotherapy (Docetaxel or Pemetrexed) for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Acetylsalicylic Acid
    • Caffeine
    Czechia France Germany Greece Italy Poland +1

  • Study Comparing Brentuximab Vedotin with Drug Combination for Treating Advanced Classical Hodgkin Lymphoma in Patients

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Bleomycin
    • Brentuximab Vedotin
    • Vinblastine Sulfate
    Belgium Czechia Denmark France Hungary Italy +3

  • Study on Long-term Safety and Effects of ARGX-117 for Adults with Multifocal Motor Neuropathy

    Not recruiting

    2 1
    Investigated Diseases:
    • Multifocal motor neuropathy
    Investigated Drugs:
    • Empasiprubart
    Austria Belgium France Germany Italy The Netherlands +2

  • Study of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Acp-017
    • Transcon Il-2Β/Γ
    • Pembrolizumab
    Germany Hungary Italy Poland Spain

  • Study on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic spontaneous urticaria
    Investigated Drugs:
    • Omalizumab
    • Remibrutinib
    Bulgaria Czechia France Germany Hungary Italy +4
Previous Page
1 … 46 47 48 49 50 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!